8th Jul 2019 09:29
(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.
The double-blind, placebo-controlled study will enrol 90 patients "not adequately controlled on their current inhaler maintenance therapy. 4d said the patients will take the candidate, MRx-4DP0004, as well any existing maintenance therapy.
The company said this is the world's first clinical study of a live biotherapeutic in patients with poorly controlled asthma. 4d expects the results from the study to be available in 2020.
"Commencing this study further underlines 4D's commitment to unlocking the full potential of the gut microbiome and live biotherapeutics or 'LBPs' to treat diseases beyond the gastrointestinal tract. This year, we have expanded our clinical pipeline to evaluate LBPs in diseases anatomically distant from the gut, firstly in oncology, and now in asthma," 4d Chief Scientific Officer Alex Stevenson said.
He added: "Despite available therapies, many asthma patients struggle to achieve control of their disease and suffer from exacerbations often requiring hospitalisation. The results from this study will be an important proof-of-concept in the development of live biotherapeutics as a next generation therapy in asthma management."
Shares in 4d Pharma were untraded in London on Monday but last closed at 91.50 pence each.
Related Shares:
DDDD.L